Medical Oncology and Tumor Pharmacotherapy

, Volume 3, Issue 2, pp 105–110 | Cite as

A pharmacokinetic study of adriamycin and 4′epi-adriamycin after simultaneous intra-arterial liver administration

  • Staffan Eksborg
  • Magnus Andersson
  • Lennart Domellöf
  • Ulla Lönroth


The plasma pharmacokinetics of adriamycin and 4′epi-adriamycin were studied in patients with malignant tumors of the liver after simultaneous regional administration of equal amounts of the two anthracyclines by the arterial route. The use of a highly selective liquid chromatographic analytical method permitted quantification of plasma concentrations of the two drugs as well as their corresponding 13-hydroxy metabolites.

The plasma concentrations of each drug followed a three-compartment open model. On average the area under the plasma concentration time curve (AUC) and the maximum plasma concentration (C max) were 2.1 and 1.7 times larger for adriamycin than for 4′epi-adriamycin, respectively. 4′Epi-adriamycin was eliminated faster than adriamycin, the terminal half-life time being on the average 1.5 times higher for adriamycin. These findings are in agreement with what has previously been observed after intravenous administration.

The plasma concentrations of the 13-hydroxy metabolites did not exceed 30 ng ml−1. The AUC values of these metabolites were on average 20% of the AUC values of the intact drugs.

Key words

Anthraquinone glycosides Adriamycin Epirubicin Pharmacokinetics Chemotherapy Intraarterial Liver cancer 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Ignoffo R J, Øie S, Friedman M A: Pharmacokinetics of methotrexate administered via the hepatic artery.Cancer Chemother Pharmacol 5, 217 (1981).PubMedCrossRefGoogle Scholar
  2. 2.
    Mattsson W, Jonsson K, Hellekant C, Hallsten L: Short-term intra-arterial Mitomycin C in hepatic metastases.Acta Radiol 19, 321 (1980).Google Scholar
  3. 3.
    Buchwald H, Grage T B, Vassilopoulos P P, Rodhe T D, Varco R L, Blackshear P J: Intraarterial infusion chemotherapy for hepatic carcinoma using a totally implantable infusion pump.Cancer 45, 866 (1980).PubMedCrossRefGoogle Scholar
  4. 4.
    Ensminger W D, Rosowsky A, Raso V, Levin D C, Glode M, Come S, Steele G, Frei E III: A clinical-pharmacological evaluation of hepatic arterial infusions of 5-fluoro-2′-deoxyuridine and 5-fluorouracil.Cancer Res 38, 3784 (1978).PubMedGoogle Scholar
  5. 5.
    Lee Y-T N, Irwin L: Hepatic artery ligation and adriamycin infusion chemotherapy for hepatoma.Cancer 41, 1249 (1978).PubMedCrossRefGoogle Scholar
  6. 6.
    Lee Y-T, Chan K K, Harris P A, Cohen J L: Distribution of adriamycin in cancer patients. Tissue uptakes, plasma concentration after IV and hepatic IA administration.Cancer 45, 2231 (1980).PubMedCrossRefGoogle Scholar
  7. 7.
    Bern M M, McDermott W Jr, Cady B, Oberfield R A, Trey C, Clouse M E, Tullis J L, Parker L M: Intraarterial hepatic infusion and intravenous adriamycin for treatment of hepatocellular carcinoma: a clinical and pharmacology report.Cancer 42, 399 (1978).PubMedCrossRefGoogle Scholar
  8. 8.
    Garnick M B, Ensminger W D, Israel M: A clinical pharmacological evaluation of hepatic arterial infusion of adriamycin.Cancer Res 39, 4105 (1979).PubMedGoogle Scholar
  9. 9.
    Chlebowski R T, Chan K K, Tong M J, Weiner J M, Ryden V M J, Bateman J R: Adriamycin and methyl-CCNU combination therapy in hepatocellular carcinoma: clinical and pharmacokinetic aspects.Cancer 48, 1088 (1981).PubMedCrossRefGoogle Scholar
  10. 10.
    Ganzina F: 4-Epi-doxorubicin, a new analog of doxorubicin: a preliminary overview of preclinical and clinical data.Cancer Treatment Rev 10, 1 (1983).CrossRefGoogle Scholar
  11. 11.
    Hurteloup P, Cappelaere P, Armand J P, Mathé G: Phase II clinical evaluation of 4′-epi-doxorubicin.Cancer Treatment Rep 67, 337 (1983).Google Scholar
  12. 12.
    Naguse N, Yukaya H, Suehiro S: Intra-arterial administration of 4′-epi-adriamycin in the treatment of hepatocellular carcinoma.Proc 2nd Int Workshop for Chemotherapy of Hepatic Tumors, Sendai, 28 September, pp. 76–85 (1983).Google Scholar
  13. 13.
    Kuroda C, Okamura J, Tanaka T, Tokunaga K, Hori S, Yoshioka H, Sakurai M: Effect of transcatheter intra-arterial infusion of 4′epi-adriamycin in a case of hepatocellular carcinoma with tumor thrombi in the portal vein.Proc 2nd Int Workshop for Chemotherapy of Hepatic Tumors, Sendai, 28 September, pp. 86–92 (1983).Google Scholar
  14. 14.
    Strocchi E, Camaggi C M, Rossi A P, Angelelli B, Comparsi R, Franchini A, Del Prete P, Cola B, Pannuti F: Epirubicin pharmacokinetics after intrahepatic arterial and intraperitoneal administration.Drugs Exp Clin Res 11, 295 (1985).PubMedGoogle Scholar
  15. 15.
    Eksborg S, Ehrsson H: Liquid chromatography in anticancer drug research with special reference to anthraquinone glycosides.J Pharmac Biomed Anal 2, 297 (1984).CrossRefGoogle Scholar
  16. 16.
    Eksborg S, Ehrsson H, Andersson I: Reversed-phase liquid chromatographic determination of plasma levels of adriamycin and adriamycinol.J Chromatogr 164, 479 (1979).PubMedCrossRefGoogle Scholar
  17. 17.
    Gibaldi M, Perrier D:Pharmacokinetics. New York, Marcel Dekker (1975).Google Scholar
  18. 18.
    Eksborg S, Cedermark B J, Strandler H-S: Intrahepatic and intravenous administration of adriamycin —a comparative pharmacokinetic study in patients with malignant liver tumours.Med Oncol Tumor Pharmacother 2, 47 (1985).PubMedGoogle Scholar
  19. 19.
    Eksborg S, Strandler H-S, Edsmyr F, Näslund I, Tahvanainen P: Pharmacokinetic study of IV infusions of adriamycin.Eur J Clin Pharmac 28, 205 (1985).CrossRefGoogle Scholar
  20. 20.
    Camaggi C M, Strocchi E, Tamassia V, Martoni A, Giovannini M, Iafelice G, Canova N, Marraro D, Martini A, Pannuti F: Pharmacokinetic studies of 4′-epi-doxorubicin in cancer patients with normal and impaired renal function and with hepatic metastases.Cancer Treatment Rep 66, 1819 (1982).Google Scholar
  21. 21.
    Weenen H, Lankelma J, Penders P G M, McVie J G, Ten Bokkel Huinink W W, de Planque M M, Pinedo H M: Pharmacokinetics of 4′-epi-doxorubicin in man.Invest New Drugs 1, 59 (1983).PubMedCrossRefGoogle Scholar
  22. 22.
    Martini A, Moro E, Pacciarini M A, Tamassia V, Natale N, Piazza E: Cross-over study of pharmacokinetics and haematological toxicity of 4′-epi-doxorubicin and doxorubicin in cancer patients.Int J Clin Pharmac Res 4, 231 (1984).Google Scholar
  23. 23.
    Natale N, Piazza E, Italia C, Trabattoni A, Luchini S: The kinetics of anthracyclines in human plasma and tissues: daunomycin, doxorubicin and 4′epi-doxorubicin.Drugs Exp Clin Res 9, 775 (1983).Google Scholar
  24. 24.
    Robert J, Vrignaud P, Nguyen-Ngoc T, Illiadis A, Mauriac L, Hurteloup P: Comparative pharmacokinetics and metabolism of doxorubicin and epirubicin in patients with metastatic breast cancer.Cancer Treatment Rep 69, 633 (1985).Google Scholar
  25. 25.
    Eksborg S, Stendahl U, Lönroth U: A comparative pharmacokinetic study of adriamycin and 4′epi-adriamycin after simultaneous intravenous administration.Eur J Clin Pharmac (in press).Google Scholar
  26. 26.
    Greene W, Huffman D, Wiernik P H, Schimpff S, Benjamin R, Bachur N: High-dose daunorubicin therapy for acute nonlymphocytic leukemia: correlation of response and toxicity with pharmaockinetics and intracellular daunorubicin reductase activity.Cancer 30, 1419 (1972).PubMedCrossRefGoogle Scholar
  27. 27.
    Takanashi S, Bachur N R: Adriamycin metabolism man: evidence from urinary metabolites.Drug Met Disp 4, 79 (1976).Google Scholar
  28. 28.
    Bachur N R: Adriamycin (NSC-123127) pharmacology.Cancer Chemother Rep, Part 3 6, 153 (1975).Google Scholar
  29. 29.
    Bailey-Wood R, Dallimore C M, Whittaker J A: Effect of adriamycin on CFUGM at plasma concentrations found following therapeutic infusions.Br J Cancer 50, 351 (1984).PubMedGoogle Scholar

Copyright information

© Humana Press Inc. 1986

Authors and Affiliations

  • Staffan Eksborg
    • 1
  • Magnus Andersson
    • 2
  • Lennart Domellöf
    • 2
  • Ulla Lönroth
    • 1
  1. 1.Karolinska PharmacyStockholm
  2. 2.Department of SurgeryUniversity HospitalUmeåSweden

Personalised recommendations